Heterochromatin protein 1 expression is reduced in human thyroid malignancy

Tretiakova, Maria; Bond, Sarah D.; Wheeler, David A.; Contreras, Alejandro; Kocherginsky, Masha; Kroll, Todd G.; Hale, Tracy K.

doi:10.1038/labinvest.2014.68

Cited by 7 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High expression of CBX1 transcript was associated with poor recurrence-free survival of patients with breast cancer [12] . On the other hand, CBX1 was reduced in thyroid carcinomas [22] . In the present study, CBX1 was markedly induced in HCC tissues.…”

Section: Discussionmentioning

confidence: 92%

CBX1 Indicates Poor Outcomes and Exerts Oncogenic Activity in Hepatocellular Carcinoma

Yang

Pan

Qing

et al. 2018

Translational Oncology

View full text Add to dashboard Cite

Dysregulation of chromobox proteins contributes to the progression of human diseases. CBX1 has been implicated in epigenetic control of chromatin structure and gene expression, but its role in human cancers remains largely unknown. Here we show that CBX1 exhibits oncogenic activities in hepatocellular carcinoma (HCC) and indicates poor outcomes. The expression of CBX1 was noticeably increased, at both mRNA and protein levels, in HCC tissues and cell lines, compared with the nontumorous ones. High CBX1 expression was significantly associated with larger tumor size, poor tumor differentiation and tumor vascular invasion. Patients with elevated expression of CBX1 were frequently accompanied with unfavorable overall and disease-free survivals in two independent cohorts consisting of 648 HCC cases. The prognostic value of CBX1 was further confirmed by stratified survival analyses. Multivariate cox regression model suggested CBX1 as an independent factor for overall survival (hazard ratio = 1.735, 95% confident interval: 1.342–2.244, P < .001). In vitro data demonstrated that CBX1 overexpression promoted cell proliferation and migration, whereas the knockdown of CBX1 resulted in the opposite phenotypes. Mechanistically, CBX1 interacted with transcription factor HMGA2 to activate the Wnt/β-Catenin signaling pathway. Suppression of β-Catenin by siRNA or specific inhibitor XAV-939 markedly attenuated CBX1-mediated cell growth. Collectively, our findings indicate that CBX1 functions as an oncogene and may serve as a potential prognostic biomarker in HCC.

show abstract

Section: Discussionmentioning

confidence: 92%

CBX1 Indicates Poor Outcomes and Exerts Oncogenic Activity in Hepatocellular Carcinoma

Yang

Pan

Qing

et al. 2018

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…In addition, high expression of CBX1 was markedly correlated with larger tumor size, poor tumor differentiation, and tumor vascular invasion in hepatocellular carcinoma [33]. However, Tretiakova et al [34] reported that the expression of CBX1 was lower in thyroid carcinoma, and the decrease in CBX1 followed by a reduction in CBX5 contributed to the pathogenesis of thyroid carcinoma. Our study indicated that CBX1 mRNA expression was upregulated in GC patients, which was in accordance with the data in other tumors.…”

Section: Discussionmentioning

confidence: 98%

Identification of the Roles of Chromobox Family Members in Gastric Cancer: A Study Based on Multiple Datasets

Chen

Sun

Zhu

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. As the important components in polycomb repressive complexes 1 (PRC1) and heterochromatin protein 1 (HP1), Chromobox (CBX) family members are involved in epigenetic regulatory function, transcriptional repression, and other cellular metabolisms. Increasing studies have indicated significant associations between CBX and tumorigenesis, which is a progression in different types of cancers. However, the information about the roles of each CBX in gastric cancer is extremely limited. Methods. We explored CBX mRNA expression, corrections with clinicopathological parameters, protein expression, prognostic values, enrichment analysis with several databases including Oncomine, Human Protein Atlas, UALCAN, Kaplan-Meier plotter, cBioPortal, GeneMANIA, and Enrichr. Results. In our study, comparing to the normal tissues, higher mRNA expression of CBX1/2/3/4/5/8 and lower mRNA expression of CBX7 were found in GC tissues while upregulations of CBX1/2/3/4/5/8 and downregulations of CBX7 were indicated to be significantly correlated to the nodal metastasis status and individual cancer stages in GC patients. As for protein level, the expression of CBX2/3/4/5/6 was higher and the expression of CBX7 was lower in the GC tissues than those in the normal. What is more, higher mRNA expression of CBX1/5/6/8 and lower mRNA expression of CBX7 were markedly correlated to poor outcomes of OS and FP in GC patients. Besides, high mutation rate of CBXs (42%) was observed in GC patients. Conclusions. We suggest that CBX5/7 may serve as potential therapeutic targets for GC while CBX1/8 may serve as potential prognostic indicators for GC.

show abstract

“…It may be related to the inhibitory effect of miRNAs that are highly expressed in thyroid cancer (miR-205, etc.) (31). Also, CBX1 expression increases in breast cancer and is associated with poor prognosis in breast cancer patient (32).…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of the prognosis for chromobox family in gastric cancer

Kang

Zhu

et al. 2020

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Chromobox (CBX) family proteins are a class of transcriptional repressors involved in epigenetic regulation and developmental processes of various tumors, including gastric cancer. However, the function and prognosis of different CBXs in gastric cancer remain unknown. Methods: This study addresses this issue by synthesizing several mainstream databases (Oncomine, GEPIA2, cBioportal, and Kaplan-Meier plotter, among others) that currently contain many tumor samples and provide very reliable analysis results, investigating the role of CBXs in the prognosis of gastric cancer. Results: The mRNA of CBX1/2/3/4/5/8 was highly expressed in gastric cancer, the mRNA of CBX7 was lowly expressed in gastric cancer, and the mRNA expression of CBX6 was not significantly different in CRC. Besides, high and low CBXs mRNA expression correlated with cancer stage, node metastasis status, H. pylori infection status, and tumor grade in CRC patients. We found that high mRNA expression of CBX4/5/6/7/8 was significantly associated with worse overall survival (OS), progression-free survival (FP), and post-progression survival (PPS) in a large number of CRC patients. High mRNA expression of CBX3 was significantly associated with better OS and FP. We also found that none of the eight CBXs family genes had a mutation rate of less than 5% in gastric cancer, and the highest mutation rate was in CBX3 (14%). Conclusions: These results suggest that CBX3/4/5/6/7/8 could be a prognostic biomarker in gastric cancer patients.

show abstract

Heterochromatin protein 1 expression is reduced in human thyroid malignancy

Cited by 7 publications

References 25 publications

CBX1 Indicates Poor Outcomes and Exerts Oncogenic Activity in Hepatocellular Carcinoma

CBX1 Indicates Poor Outcomes and Exerts Oncogenic Activity in Hepatocellular Carcinoma

Identification of the Roles of Chromobox Family Members in Gastric Cancer: A Study Based on Multiple Datasets

Comprehensive analysis of the prognosis for chromobox family in gastric cancer

Contact Info

Product

Resources

About